Cargando…

Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity

PURPOSE: Vestibulotoxicity associated with cisplatin chemotherapy is known to exist, but the extent, severity, and impact is unclear from the literature. This study explored knowledge, experiences, and opinions of audiovestibular professionals about cisplatin vestibulotoxicity. METHODS: An online su...

Descripción completa

Detalles Bibliográficos
Autores principales: Prayuenyong, Pattarawadee, Kasbekar, Anand V., Hall, Deborah A., Baguley, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648001/
https://www.ncbi.nlm.nih.gov/pubmed/32430772
http://dx.doi.org/10.1007/s00405-020-06033-4
_version_ 1783607023668035584
author Prayuenyong, Pattarawadee
Kasbekar, Anand V.
Hall, Deborah A.
Baguley, David M.
author_facet Prayuenyong, Pattarawadee
Kasbekar, Anand V.
Hall, Deborah A.
Baguley, David M.
author_sort Prayuenyong, Pattarawadee
collection PubMed
description PURPOSE: Vestibulotoxicity associated with cisplatin chemotherapy is known to exist, but the extent, severity, and impact is unclear from the literature. This study explored knowledge, experiences, and opinions of audiovestibular professionals about cisplatin vestibulotoxicity. METHODS: An online survey was disseminated to clinicians working in the audiovestibular field. RESULTS: Ninety-three respondents participated in the survey. Most professionals were aware of potential vestibulotoxicity associated with cisplatin chemotherapy. Thirty-three percent of the respondents reported that they had seen patients with cisplatin vestibulotoxicity. Forty percent of them were confident in making the diagnosis and in managing the patient in this situation. The prevalence and impact of vestibulotoxicity including practicality of the assessment should be considered when designing an effective vestibulotoxicity screening protocol. CONCLUSION: This study provides a better understanding of cisplatin vestibulotoxicity from the perspectives of audiovestibular clinicians, which will underpin appropriate detection and management of the condition.
format Online
Article
Text
id pubmed-7648001
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76480012020-11-10 Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity Prayuenyong, Pattarawadee Kasbekar, Anand V. Hall, Deborah A. Baguley, David M. Eur Arch Otorhinolaryngol Otology PURPOSE: Vestibulotoxicity associated with cisplatin chemotherapy is known to exist, but the extent, severity, and impact is unclear from the literature. This study explored knowledge, experiences, and opinions of audiovestibular professionals about cisplatin vestibulotoxicity. METHODS: An online survey was disseminated to clinicians working in the audiovestibular field. RESULTS: Ninety-three respondents participated in the survey. Most professionals were aware of potential vestibulotoxicity associated with cisplatin chemotherapy. Thirty-three percent of the respondents reported that they had seen patients with cisplatin vestibulotoxicity. Forty percent of them were confident in making the diagnosis and in managing the patient in this situation. The prevalence and impact of vestibulotoxicity including practicality of the assessment should be considered when designing an effective vestibulotoxicity screening protocol. CONCLUSION: This study provides a better understanding of cisplatin vestibulotoxicity from the perspectives of audiovestibular clinicians, which will underpin appropriate detection and management of the condition. Springer Berlin Heidelberg 2020-05-19 2020 /pmc/articles/PMC7648001/ /pubmed/32430772 http://dx.doi.org/10.1007/s00405-020-06033-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Otology
Prayuenyong, Pattarawadee
Kasbekar, Anand V.
Hall, Deborah A.
Baguley, David M.
Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title_full Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title_fullStr Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title_full_unstemmed Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title_short Audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
title_sort audiovestibular clinician experiences and opinions about cisplatin vestibulotoxicity
topic Otology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648001/
https://www.ncbi.nlm.nih.gov/pubmed/32430772
http://dx.doi.org/10.1007/s00405-020-06033-4
work_keys_str_mv AT prayuenyongpattarawadee audiovestibularclinicianexperiencesandopinionsaboutcisplatinvestibulotoxicity
AT kasbekaranandv audiovestibularclinicianexperiencesandopinionsaboutcisplatinvestibulotoxicity
AT halldeboraha audiovestibularclinicianexperiencesandopinionsaboutcisplatinvestibulotoxicity
AT baguleydavidm audiovestibularclinicianexperiencesandopinionsaboutcisplatinvestibulotoxicity